Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows

Voyager Therapeutics

06/08/2026 21:13

Overview
US biotech firm's Q2 collaboration revenue fell yr/yr as Neurocrine activities moved past research phase
Q2 net loss narrowed from prior year as R&D and G&A expenses declined
Company ended Q2 with $149 mln cash, expects runway into 2028

Outlook
Voyager expects to begin dosing VY1706 in early Alzheimer's patients in Q4 2026
Company anticipates tau PET imaging data for VY7523 in Q4 2026
Voyager expects its cash position to fund operations into 2028

Result Drivers
COLLABORATION REVENUE DECLINE - Co said lower Q2 collaboration revenue was due to reduced revenue from the Neurocrine agreement as activities transition beyond the research phase
LOWER R&D EXPENSES - Co attributed decreased Q2 research and development expenses to program and platform prioritization
REDUCED G&A COSTS - Co said general and administrative expenses declined due to restructuring actions in 2025

Company press release: ID:nGNX4gPzt9

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$3.17 mln
 
Q2 Net Loss
 
$24.47 mln
 
Q2 Loss Per Basic Share
 
$0.40
 
Q2 Operating Income
 
-$26.39 mln
 
Q2 Pretax Loss
 
$24.45 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Voyager Therapeutics, Inc. is $12.00, about 287.1% above its August 5 closing price of $3.10

Reuters Recommended Reads
Aug 6 - Intellia Therapeutics Q2 collaboration revenue falls, net loss widens
Aug 5 - Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Aug 6 - Prime Medicine Q2 net loss narrows on lower expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)